| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | -141.10% | -177.96% | -251.18% | -368.99% | -203.31% | -189.96% |
| EBITDA Margin | -131.42% | -165.97% | -237.39% | -352.43% | -196.72% | -180.57% |
| Net Margin | -140.30% | -167.16% | -232.99% | -354.91% | -316.48% | -230.63% |
| Current Ratio | 3.31 | 4.61 | 6.34 | 7.27 | 12.01 | 4.00 |
| Quick Ratio | 2.36 | 3.46 | 5.29 | 6.16 | 11.14 | 3.42 |
| Debt / Equity | 0.57 | 0.00 | — | 0.00 | 0.00 | -0.20 |
| ROE | -141.91% | -62.23% | -44.47% | -37.04% | -33.27% | 29.19% |
| ROA | -62.95% | -47.76% | -36.57% | -31.89% | -30.49% | -52.97% |
| Asset Turnover | 0.45 | 0.29 | 0.16 | 0.09 | 0.10 | 0.23 |
| Book Value / Share | 0.74 | 1.73 | 2.74 | 3.87 | 11.17 | -354.19 |
Rapid Micro Biosystems, Inc. is a prominent entity in the life sciences sector, focusing on automation solutions for microbial detection in pharmaceutical manufacturing. The company's primary function is to enhance quality control processes through advanced technologies, enabling quicker and more reliable detection of microbial contamination. Rapid Micro Biosystems operates in an industry that demands stringent safety and regulatory compliance, thus playing a crucial role in ensuring product integrity and patient safety. Its innovative detection systems, designed to meet the needs of biopharmaceutical companies and related industries, underscore significant technological advancements in microbial quality control. As the company continues to evolve within its market, it actively contributes to improving operational efficiency and safeguarding public health through cutting-edge scientific solutions.